Clinical trials: Adnexal Tumor
Prehabilitation, Cancer of Colon
Abdominopelvic Cancer Prehabilitation
The main objective of this research is to determine the effectiveness of a Prehabilitation consultation in self-care and physical exercise aimed at patients diagnosed with abdominopelvic cancer with initial surgical indication as…
- Conditions
- Prehabilitation, Cancer of Colon, Cancer of Rectum, Cancer, Ovarian
- Trial name
- NCT05887531
- Testing
- Prehabilitation
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- Universitat Jaume I
Ovarian Cancer
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
This prospective observational study is to assess the dynamics of circulating tumor DNA (ctDNA) in patients with advanced epithelial ovarian cancer (EOC) undergoing surgery, adjuvant chemotherapy, followed by poly adenosine…
- Trial name
- EOC (NCT05446545)
- Testing
- ND-EOC or platinum-sensitive rEOC
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Fudan University
Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
The study aims to obtain a local control rate in patients with lateral pelvic relapses of gynecologycal cancers previously irradiated.
- Conditions
- Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva, Malignant Epithelial Tumor of Ovary, Malignant Epithelial Neoplasm
- Trial name
- CYCLOPS (NCT05457595)
- Testing
- carbon ion radiation therapy
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Leukemia, Myeloid, Acute, Myeloid Dysplasia
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
Therapy related acute myeloid leukemia and myelodysplasia (t-MN) is a potential late complication of cytotoxic therapy, and it is of particular concern in the treatment of patients with epithelial ovarian carcinoma (EOC) exposed…
- Conditions
- Leukemia, Myeloid, Acute, Myeloid Dysplasia, Ovarian Epithelial Cancer
- Trial name
- NCT06785077
- Testing
- buccal cells, bone marrow cells, peripheral blood cells
- Where
- Italy
- Volunteers
- 157 people
- Sponsor
- European Institute of Oncology
Epithelial Ovarian Cancer, Primary Peritoneal
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
- Trial name
- NCT06690775
- Testing
- TORL-1-23, Pegfilgrastim (drug)
- Where
- 66 sites in United States, Australia and 10 more
- Volunteers
- 230 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovarian Cancer
MicroFluO: FLUorescence-guided Surgery for Ovarian Cancer
Epithelial ovarian cancers (EOC) are discovered in 75% of cases at an advanced stage, marked by the presence of peritoneal carcinomatosis.
- Trial name
- MicroFluO (NCT05633836)
- Testing
- Fluorescence guided surgery
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
The purpose of this study is to determine the objective response rate of ABT-888 when given in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian…
- Trial name
- NCT01113957
- Testing
- ABT-888, pegylated liposomal doxorubicin, temozolomide
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 168 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
This clinical trial studies how well ultrasound microvessel imaging (UMI) works in evaluating ovarian and adnexal lesions in patients who are scheduled to have surgical treatment for their ovarian or adnexal lesions as part of…
- Conditions
- Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma, Female Reproductive System Neoplasm, Ovarian Neoplasms
- Trial name
- NCT07280312
- Testing
- Transvaginal Ultrasound, Ultrasound Microvessel Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Ovarian Neoplasms
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart.
- Trial name
- NCT00034372
- Testing
- oregovomab
- Where
- 17 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Unither Pharmaceuticals
Ovarian Cancer
Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study
The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian…
- Trial name
- GREKO III (NCT03464201)
- Testing
- Enzalutamide 40 MG
- Where
- 8 sites in Spain
- Volunteers
- 16 people
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
Ovarian Cancer
Surgeons' Ability to Predict Pathological and Molecular Features of Peritoneal Carcinomatosis in Ovarian Cancer
Epithelial ovarian cancer (EOC) presents with peritoneal carcinomatosis (PC) at diagnosis in approximately two-thirds of cases. Diagnostic laparoscopy is pivotal to assess disease extent and to guide the choice between primary…
- Trial name
- Visual-PC (NCT07321730)
- Testing
- VISUAL PC - SURVEY 2.0
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ovarian Cancer, Adnexal Mass
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.
- Trial name
- NCT04051502
- Testing
- Method 1: Indocyanine green dye, Method 2: Indocyanine green dye, Method 3: Indocyanine green dye
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ovarian Cancer
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Trial name
- NCT00849667
- Testing
- Farletuzumab, Carboplatin, Taxane
- Where
- 375 sites in United States, Argentina and 28 more
- Volunteers
- 1,100 people
- Sponsor
- Morphotek
Ovarian Cyst
Effects of Adrenergic Drugs on the Fluid Balance During Surgery
The aim this study was to examine to what degree the slow turnover of lactated Ringer's solution during anesthesia and surgery can be prevented by infusing esmolol (a ß1-receptor blocker) or phenylephrine in patients undergoing…
- Trial name
- NCT01431612
- Testing
- Esmolol administration, Phenylephrine infusion, Lactated Ringer´s solution
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sodertalje Hospital
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.